Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Unicycive Therapeutics (UNCY) Gains from Investment Securities (2020 - 2026)

Unicycive Therapeutics filings provide 3 years of Gains from Investment Securities readings, the most recent being $5.8 million for Q4 2024.

  • On a quarterly basis, Gains from Investment Securities rose 8087.5% to $5.8 million in Q4 2024 year-over-year; TTM through Dec 2024 was $676000.0, a N/A change, with the full-year FY2025 number at -$2.0 million, down 247.83% from a year prior.
  • Gains from Investment Securities hit $5.8 million in Q4 2024 for Unicycive Therapeutics, down from $13.7 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $13.7 million in Q3 2024 to a low of -$16.8 million in Q2 2024.
  • Median Gains from Investment Securities over the past 3 years was $5.8 million (2024), compared with a mean of $4.2 million.
  • The widest YoY moves for Gains from Investment Securities: up 8087.5% in 2024, down 1359.83% in 2024.
  • Unicycive Therapeutics' Gains from Investment Securities stood at $1.3 million in 2022, then crashed by 105.36% to -$72000.0 in 2023, then surged by 8087.5% to $5.8 million in 2024.
  • The last three reported values for Gains from Investment Securities were $5.8 million (Q4 2024), $13.7 million (Q3 2024), and -$16.8 million (Q2 2024) per Business Quant data.